Breast cancer in the early-stage setting
Fondazione Oncotech Impresa Sociale supports clinical research in ER-positive, HER2-negative breast cancer, with a particular focus on patients with early breast cancer and hormone receptor-positive disease. The funded studies concentrate on treatment strategies used before surgery and on clinical questions relevant to localized disease management.
- Neoadjuvant therapy in ER-positive, HER2-negative breast cancer
- Early-stage breast cancer
- Hormone receptor-positive disease
The sponsor’s research activity is centered on improving care in a defined breast oncology population through studies conducted at multiple collaborating sites in Italy.
Cell-cycle inhibition and endocrine-based treatment
One area of interest involves combinations of CDK4/6 inhibition and estrogen receptor targeting in breast cancer. The sponsored trials examine treatment approaches that integrate abemaciclib and giredestrant in the neoadjuvant context for ER-positive, HER2-negative disease.
- Abemaciclib
- Giredestrant
- Cell-cycle arrest
These studies reflect a therapeutic focus on targeted oncology for patients with early hormone receptor-positive breast cancer.
Supportive care for systemic breast cancer therapy
The sponsor also funds research addressing treatment-related toxicity in breast cancer, with attention to liver-related safety concerns during Ribociclib and endocrine therapy use. This includes investigation of approaches intended to reduce hepatotoxicity associated with ongoing cancer treatment.
- Ribociclib-related hepatotoxicity
- AST/ALT elevation
- Safety in breast cancer treatment
Clinical interest extends beyond antitumor activity to the tolerability of systemic therapy in patients receiving treatment for hormone receptor-positive breast cancer.
